4.7 Article

C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Biochemistry & Molecular Biology

Utility of Measuring Serum Concentrations of Anti-TNF Agents and Anti-Drug Antibodies in Inflammatory Bowel Disease

Ivan Guerra et al.

CURRENT DRUG METABOLISM (2013)

Article Gastroenterology & Hepatology

Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease

Matthias Jurgens et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)

Article Biochemical Research Methods

Single molecule measurements of tumor necrosis factor α and interleukin-6 in the plasma of patients with Crohn's disease

Linan Song et al.

JOURNAL OF IMMUNOLOGICAL METHODS (2011)

Review Gastroenterology & Hepatology

The Natural History of Adult Crohn's Disease in Population-Based Cohorts

Laurent Peyrin-Biroulet et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)

Article Gastroenterology & Hepatology

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

Waqqas Afif et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)

Review Gastroenterology & Hepatology

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

Javier P. Gisbert et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)

Article Gastroenterology & Hepatology

Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease

Elana A. Maser et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)

Review Gastroenterology & Hepatology

Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis

RB Sartor

NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY (2006)

Review Gastroenterology & Hepatology

Oratory markers in IBD: Magic, or unneccessary toys?

S Vermeire et al.

Article Medicine, General & Internal

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

SB Hanauer et al.

LANCET (2002)